Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Puma posts flat Q1 sales, holds outlook but no guidance on tariffs

(Sharecast News) - Puma reported a fall in first-quarter profits and flat sales as the German sportswear giant declined to provide any estimates on the potential hit from US tariffs. Operating profit fell 52% year-on-year to €76m, less than the 58% decrease expected by analysts. Sales came in higher than estimated at €2.076bn, a rise of 0.1% year on year and forecasts of €2.04bn.

The company, which has a large manufacturing base in Asia, did say it had moved to reduce its US imports from China after warning in March that it expected an impact from President Donald Trump's tariff policy.

"Due to the highly uncertain implications from the US tariffs, we are not quantifying the potential implications at this stage," said chief financial officer Markus Neubrand in a statement.

Rival Adidas last week warned that the levies would lead to price hikes for all of its US products.

Puma continued to forecast 2025 sales growth in the low- to mid-single-digit percentage range, and operating profit excluding one-time costs of €520m - 600m.

Weak US sales contributed to a 2.7% sales decline in the Americas amid soft sales in Europe and Asia-Pacific, notably China.

The company also maintained its 2025 earnings targets, but acknowledged that its outlook ignored the potential impacts of US President Donald Trump's erratic tariff policies.

Puma in April parted company with chief executive Arne Freundt after a disagreement with the supervisory board over its sales strategy. It is awaiting the arrival of Adidas veteran Arthur Hoeld as CEO in July.

In March, Puma disappointed investors with a gloomy trading update based on trade tariffs, currency swings and escalating geopolitical tensions.

It also said adjusted earnings before interest and taxes would probably fall this year to between €520 million and €600 million, while currency-adjusted sales would only grow in the low- to mid-single-digit range.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.